Since the literature demonstrated a survival benefit for patients with EGFR/ALK-positive NSCLC after they received adjuvant targeted therapy, this inspired researchers to investigate the utility of neoadjuvant targeted therapy (Table 3). The gene discussed is ALK; the disease is non-small cell lung carcinoma.